Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species
- 26 May 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (13), 7226-7242
- https://doi.org/10.1021/acs.jmedchem.0c00464
Abstract
Oral factor XIa (FXIa) inhibitors may provide a promising new antithrombotic therapy with an improved benefit to bleeding risk profile over existing antithrombotic agents. Herein, we report application of a previously disclosed cyclic carbamate P1 linker which provided improved oral bioavailability in the imidazole-based 13-membered macrocycle to the 12-membered macrocycle. This resulted in identification of compound 4 with desired FXIa inhibitory potency and good oral bioavailability but high in vivo clearance. Further structure-activity relationship (SAR) studies of heterocyclic core modifications to replace the imidazole core as well as various linkers to the P1 group led to the discovery of compound 6f, a potent FXIa inhibitor with selectivity against most of the relevant serine proteases. Compound 6f also demonstrated excellent pharmacokinetics (PK) profile (high oral bioavailability and low clearance) in multiple preclinical species. Compound 6f achieved robust antithrombotic efficacy in a rabbit efficacy model at doses which preserved hemostasis.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 29 references indexed in Scilit:
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2018
- Factor XIa Inhibitors as New AnticoagulantsJournal of Medicinal Chemistry, 2018
- Recent advances in the discovery and development of factor XI/XIa inhibitorsMedicinal Research Reviews, 2018
- Factor XI and contact activation as targets for antithrombotic therapyJournal of Thrombosis and Haemostasis, 2015
- Overview of the New Oral AnticoagulantsArteriosclerosis, Thrombosis, and Vascular Biology, 2015
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Factor XI deficiency in humansJournal of Thrombosis and Haemostasis, 2009
- Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XIBlood, 2009
- Reduced incidence of ischemic stroke in patients with severe factor XI deficiencyBlood, 2008
- Elevated Factor XI Activity Levels Are Associated With an Increased Odds Ratio for Cerebrovascular EventsAmerican Journal of Clinical Pathology, 2006